Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: A post-hoc analysis of a randomized controlled trial

Expert Opinion on Biological Therapy

Volumn 13, Issue 12, 2013, Pages 1643-1651

  Jones, Mitchell L ^a,b   Martoni, Christopher J ^b   Ganopolsky, Jorge G ^b   Sulemankhil, Imran ^a   Ghali, Peter ^c   Prakash, Satya ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Bile salt hydrolase; Gastrointestinal health status; Lactobacillus reuteri; Probiotic; Rome III questionnaire

Indexed keywords

BILE SALT HYDROLASE; CARDIOVIVA; HYDROLASE; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONSTIPATION; DIARRHEA; DRUG CAPSULE; DRUG TOLERABILITY; EPIGASTRIC BURNING; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HUMAN; HYPERCHOLESTEROLEMIA; LACTOBACILLUS REUTERI; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOMATOLOGY; TREATMENT OUTCOME;

CAPSULES; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HEALTH STATUS; HUMANS; INTERVENTION STUDIES; LACTOBACILLUS REUTERI; MALE; MIDDLE AGED; PROBIOTICS; PROGNOSIS; QUESTIONNAIRES;

EID: 84887917747     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.833601     Document Type: Article

References (45)

1. van Kerkhoven LA, Eikendal T, Laheij RJ, et al. Gastrointestinal symptoms are still common in a general Western population. Neth J Med 2008;66:18-22
2. Moser G. Functional gastrointestinal disorders. Wien Med Wochenschr 2006;156:435-40
3. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-90
4. FAO and WHO. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ont. Canada; 2002
5. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010;7:503-14
6. LERCHE M, REUTER G. [A contribution to the method of isolation and differentiation of aerobic "lactobacilli" (Genus "Lactobacillus Beijerinck")]. Zentralbl Bakteriol 1960;179:354-70
7. Tong JL, Ran ZH, Shen J, et al. Metaanalysis: The effect ofSupplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-68
8. Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: A double-blind, randomized, placebo-controlled study. J Pediatr 2010;157:598-602
9. Cimperman L, Bayless G, Best K, et al. A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 2011;45:785-9
10. Shornikova AV, Casas IA, Mykkanen H, et al. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997;16:1103-7
11. Shornikova AV, Casas IA, Isolauri E, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997;24:399-404
12. Francavilla R, Lionetti E, Castellaneta SP, et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: A pilot study. Helicobacter 2008;13:127-34
13. Imase K, Tanaka A, Tokunaga K, et al. Lactobacillus reuteri tablets suppress Helicobacter pylori infection-a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi 2007;81:387-93
14. Lionetti E, Miniello VL, Castellaneta SP, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: A randomized placebo controlled trial. Aliment Pharmacol Ther 2006;24:1461-8
15. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010;299:G1087-96
16. Branton WB, Jones ML, Tomaro-Duchesneau C, et al. In vitro characterization and safety of the probiotic strain Lactobacillus reuteri cardioviva NCIMB 30242. Int J Probiotics Prebiotics 2011;6:1-12
17. Shimotoyodome A, Meguro S, Hase T, et al. Decreased colonic mucus in rats with loperamide-induced constipation. Comp Biochem Physiol A Mol Integr Physiol 2000;126:203-12
18. Klinkspoor JH, Mok KS, Van Klinken BJ, et al. Mucin secretion by the human colon cell line LS174T is regulated by bile salts. Glycobiology 1999;9:13-19
19. Lepercq P, Relano P, Cayuela C, Juste C. Bifidobacterium animalis strain DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. Scand J Gastroenterol 2004;39:1266-71
20. Marteau P, Cuillerier E, Meance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: A double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002;16:587-93
21. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
22. Jones ML, Martoni CJ, Prakash S. Letter to the editor regarding the report of Duboc et al: Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease. Gut 2013;62:654-5
23. Jones ML, Martoni CJ, Tamber S, et al. Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: A randomized, placebo-controlled, double-blind study. Food Chem Toxicol 2012;50:2216-23
24. Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: A randomized controlled trial. Eur J Clin Nutr 2012;66:1234-41
25. Jones ML, Martoni CJ, Di PE, et al. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242Supplement capsule: A randomized control trial. Regul Toxicol Pharmacol 2012;63:313-20
26. Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr 2012;107:1505-13
27. Wyrwich KW, Tardino VM. A blueprint for symptom scales and responses: Measurement and reporting. Gut 2004;53Suppl 4:iv45-8
28. Rome Foundation. Guidelines-Rome III diagnostic criteria for functional Gastrointestinal disorders. J Gastrointestin Liver Dis 2006;15:307-12
29. Scaldaferri F, Pizzoferrato M, Pecere S, et al. Bacterial flora as a cause or treatment of chronic diarrhea. Gastroenterol Clin North Am 2012;41:581-602
30. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011;45Suppl:S149-53
31. Ng SC, Hart AL, Kamm MA, et al. Mechanisms of action of probiotics: Recent advances. Inflamm Bowel Dis 2009;15:300-10
32. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004;286:G613-26
33. Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:513-17
34. Chadwick VS, Gaginella TS, Carlson GL, et al. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med 1979;94:661-74
35. Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011;60:463-72
36. Ogilvie LA, Jones BV. Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: A mechanism and marker of disease? Gut 2012;61:1642-3
37. Bercik P, Collins SM, Verdu EF. Microbes and the gut-brain axis. Neurogastroenterol Motil 2012;24(5):405-13
38. Bercik P, Denou E, Collins J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011;141:599-609
39. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: A rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007;19:166-72
40. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100:373-82
41. Lin HC. Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome. JAMA 2004;292:852-8
42. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007;42Suppl 17:41-7
43. Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and metaanalysis: Probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15
44. Nikfar S, Rahimi R, Rahimi F, et al. Efficacy of probiotics in irritable bowel syndrome: A meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008;51:1775-80
45. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14:2650-61